CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Covid-19 Rapid Test Kit (RAPG-COV-019)Wiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug1971 Quantitative IgG Test Wiki 1.00

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D008173 Lung Diseases, Obstructive NIH 0.33
D008171 Lung Diseases, NIH 0.26
D002318 Cardiovascular Diseases NIH 0.21
D011024 Pneumonia, Viral NIH 0.13
D011014 Pneumonia NIH 0.06

Correlated HPO Terms (4)

Name (Synonyms) Correlation
HP:0006536 Pulmonary obstruction HPO 0.33
HP:0002088 Abnormal lung morphology HPO 0.26
HP:0001626 Abnormality of the cardiovascular system HPO 0.21
HP:0002090 Pneumonia HPO 0.06

There is one clinical trial.

Clinical Trials

1 Validation of a Membrane-based Immunoassay for the Detection of IgG and IgM Antibodies to SARS-CoV-2/COVID-19

Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. The tests that are currently being investigated by RRI include: A. The RAPG-COV-019 kit, a small testing cartridge developed by Biopanda Reagents which detects whether an individual has been infected by the coronavirus (SARS-CoV-2) by using a spot of the person's blood and displays these results in 10 minutes. B. An already established laboratory test that detects SARS-CoV-2 by a process known as polymerase chain reaction (PCR). This test is accurate but expensive, time consuming and requires highly trained staff and laboratory facilities. C. Development of a quantitative laboratory reference test for antibodies (IgG) against the novel SARS-CoV-2 virus. The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families and visitors to their site. The RAPG-COV-019 kit can be used by non-experts and provides results within minutes, and would allow rapid, inexpensive diagnosis of coronavirus (SARS-CoV-2) infection. The results will enable determination of whether the RAPG-COV-019 kit can make a reliable diagnosis. Collecting this data also allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence and information on asymptomatic carriers. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.

NCT04404062 COVID-19 Diagnostic Test: Covid-19 Rapid Test Kit (RAPG-COV-019) Diagnostic Test: Quantitative IgG Test

Primary Outcomes

Description: Identification of trial participants who are asymptomatic carriers of SARS-CoV-2 by comparing the results of a blood finger stick test and reference laboratory tests to PCR testing for acute infection

Measure: Identification of asymptomatic carriers of SARS-CoV-2

Time: Through study completion, estimated 12 weeks

Secondary Outcomes

Description: Validation the sensitivity, specificity and reproducibility of the RAPG-COV-019 kit to detect SARS-CoV-2 infection. To help develop a quantitative laboratory reference test for antibodies (IgG) to gain an understanding of quantity of antibodies that people develop and how these decrease over time.

Measure: Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2

Time: Through study completion, estimated 12 weeks

Description: Determination of the understanding of the quantity of IgG antibodies developed as a response to SARS-CoV-2 infection, and how these antibody levels decrease over time. Antibody titres will be measured in infected individuals, over multiple days and correlated with disease parameters. This will facilitate the development of a quantitative laboratory reference test for IgG antibodies

Measure: Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2

Time: Through study completion, estimated 12 weeks

Description: Execution of an epidemiological study on SARS-CoV-2 carriage and transmission in a well-controlled clinical environment with extensive measures in place to prevent viral transmission

Measure: Exploration of SARS-CoV-2 epidemiology

Time: Through study completion, estimated 12 weeks

No related HPO nodes (Using clinical trials)